Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 3-(4-(4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
1. 760937-92-6
2. Teneligliptin [inn]
3. Teliglietin
4. [(2s,4s)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
5. Mp-513
6. Teneligliptin Hydrobromide
7. 28zhi4cf9c
8. Chembl2147777
9. Teneligliptin (inn)
10. 906093-29-6
11. {(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone
12. Unii-28zhi4cf9c
13. Teneli
14. ((2s,4s)-4-(4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(1,3-thiazolidin-3-yl)methanone
15. Cs-0882
16. Teneligliptin [mi]
17. Schembl161778
18. Teneligliptin [who-dd]
19. Gtpl9906
20. Dtxsid30997419
21. Chebi:136042
22. Mp513
23. Amy40806
24. Bdbm50391565
25. Mfcd13195565
26. Zinc36520254
27. Akos025401965
28. Db11950
29. Compound 8g [pmid: 22959556]
30. Ncgc00378896-02
31. Ncgc00378896-03
32. Ncgc00378896-04
33. ((2s,4s)-4-(4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone
34. Ac-27649
35. As-83281
36. Hy-14806
37. D08616
38. 937t926
39. Teneligliptin (contain Around 5% Hexanes)
40. Q15269678
41. ((2s,4s)-4-(4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone Hydrobromide
42. {4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone
43. 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine
44. M51
1. Teneligliptin Hbr
Molecular Weight | 426.6 g/mol |
---|---|
Molecular Formula | C22H30N6OS |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 426.22018078 g/mol |
Monoisotopic Mass | 426.22018078 g/mol |
Topological Polar Surface Area | 81.9 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 594 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
A10BH08 - Teneligliptin
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
22
PharmaCompass offers a list of Teneligliptin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Teneligliptin manufacturer or Teneligliptin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Teneligliptin manufacturer or Teneligliptin supplier.
PharmaCompass also assists you with knowing the Teneligliptin API Price utilized in the formulation of products. Teneligliptin API Price is not always fixed or binding as the Teneligliptin Price is obtained through a variety of data sources. The Teneligliptin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Teneligliptin Hydrobromide Hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Teneligliptin Hydrobromide Hydrate, including repackagers and relabelers. The FDA regulates Teneligliptin Hydrobromide Hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Teneligliptin Hydrobromide Hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Teneligliptin Hydrobromide Hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Teneligliptin Hydrobromide Hydrate supplier is an individual or a company that provides Teneligliptin Hydrobromide Hydrate active pharmaceutical ingredient (API) or Teneligliptin Hydrobromide Hydrate finished formulations upon request. The Teneligliptin Hydrobromide Hydrate suppliers may include Teneligliptin Hydrobromide Hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Teneligliptin Hydrobromide Hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Teneligliptin Hydrobromide Hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Teneligliptin Hydrobromide Hydrate active pharmaceutical ingredient (API) in detail. Different forms of Teneligliptin Hydrobromide Hydrate DMFs exist exist since differing nations have different regulations, such as Teneligliptin Hydrobromide Hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Teneligliptin Hydrobromide Hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Teneligliptin Hydrobromide Hydrate USDMF includes data on Teneligliptin Hydrobromide Hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Teneligliptin Hydrobromide Hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Teneligliptin Hydrobromide Hydrate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Teneligliptin Hydrobromide Hydrate Drug Master File in Korea (Teneligliptin Hydrobromide Hydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Teneligliptin Hydrobromide Hydrate. The MFDS reviews the Teneligliptin Hydrobromide Hydrate KDMF as part of the drug registration process and uses the information provided in the Teneligliptin Hydrobromide Hydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Teneligliptin Hydrobromide Hydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Teneligliptin Hydrobromide Hydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Teneligliptin Hydrobromide Hydrate suppliers with KDMF on PharmaCompass.
A Teneligliptin Hydrobromide Hydrate written confirmation (Teneligliptin Hydrobromide Hydrate WC) is an official document issued by a regulatory agency to a Teneligliptin Hydrobromide Hydrate manufacturer, verifying that the manufacturing facility of a Teneligliptin Hydrobromide Hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Teneligliptin Hydrobromide Hydrate APIs or Teneligliptin Hydrobromide Hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Teneligliptin Hydrobromide Hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Teneligliptin Hydrobromide Hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Teneligliptin Hydrobromide Hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Teneligliptin Hydrobromide Hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Teneligliptin Hydrobromide Hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Teneligliptin Hydrobromide Hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Teneligliptin Hydrobromide Hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Teneligliptin Hydrobromide Hydrate suppliers with NDC on PharmaCompass.
Teneligliptin Hydrobromide Hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Teneligliptin Hydrobromide Hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Teneligliptin Hydrobromide Hydrate GMP manufacturer or Teneligliptin Hydrobromide Hydrate GMP API supplier for your needs.
A Teneligliptin Hydrobromide Hydrate CoA (Certificate of Analysis) is a formal document that attests to Teneligliptin Hydrobromide Hydrate's compliance with Teneligliptin Hydrobromide Hydrate specifications and serves as a tool for batch-level quality control.
Teneligliptin Hydrobromide Hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Teneligliptin Hydrobromide Hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Teneligliptin Hydrobromide Hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Teneligliptin Hydrobromide Hydrate EP), Teneligliptin Hydrobromide Hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Teneligliptin Hydrobromide Hydrate USP).